These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6264 related articles for article (PubMed ID: 28052254)

  • 1. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
    Charoentong P; Finotello F; Angelova M; Mayer C; Efremova M; Rieder D; Hackl H; Trajanoski Z
    Cell Rep; 2017 Jan; 18(1):248-262. PubMed ID: 28052254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8
    Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW
    Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of neoantigens in response to immune checkpoint blockade.
    Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
    Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward in silico Identification of Tumor Neoantigens in Immunotherapy.
    Zhou C; Zhu C; Liu Q
    Trends Mol Med; 2019 Nov; 25(11):980-992. PubMed ID: 31494024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
    Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
    Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
    Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
    Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cancer immunotherapy by immuno-checkpoint blockade].
    Kawakami Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.
    Tamborero D; Rubio-Perez C; Muiños F; Sabarinathan R; Piulats JM; Muntasell A; Dienstmann R; Lopez-Bigas N; Gonzalez-Perez A
    Clin Cancer Res; 2018 Aug; 24(15):3717-3728. PubMed ID: 29666300
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
    Das R; Verma R; Sznol M; Boddupalli CS; Gettinger SN; Kluger H; Callahan M; Wolchok JD; Halaban R; Dhodapkar MV; Dhodapkar KM
    J Immunol; 2015 Feb; 194(3):950-9. PubMed ID: 25539810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoints and cancer in the immunogenomics era.
    Park R; Winnicki M; Liu E; Chu WM
    Brief Funct Genomics; 2019 Mar; 18(2):133-139. PubMed ID: 30137232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blockade in lymphoid malignancies.
    Thanarajasingam G; Thanarajasingam U; Ansell SM
    FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
    Roh W; Chen PL; Reuben A; Spencer CN; Prieto PA; Miller JP; Gopalakrishnan V; Wang F; Cooper ZA; Reddy SM; Gumbs C; Little L; Chang Q; Chen WS; Wani K; De Macedo MP; Chen E; Austin-Breneman JL; Jiang H; Roszik J; Tetzlaff MT; Davies MA; Gershenwald JE; Tawbi H; Lazar AJ; Hwu P; Hwu WJ; Diab A; Glitza IC; Patel SP; Woodman SE; Amaria RN; Prieto VG; Hu J; Sharma P; Allison JP; Chin L; Zhang J; Wargo JA; Futreal PA
    Sci Transl Med; 2017 Mar; 9(379):. PubMed ID: 28251903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Senant M; Giusti D; Weiss L; Dragon-Durey MA
    Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
    Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
    Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 314.